Other languages Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm Other stock markets 11:24:44 2024-05-03 EDT			5-day change	1st Jan Change
30 ^SEK	0.00%		+0.67%	-16.20%

04-15	Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	CI
02-21	Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	01-15
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	01-15
Guard Therapeutics International AB Appoints Nomination Committee for 2024	12-07
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	23-09-28
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	23-09-19
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA	23-07-14
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation	23-06-14
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Guard Therapeutics Provides Updated Information on the Phase 2 Study AKITA	23-05-02
Guard Therapeutics International AB Presents Positive Clinical Data with RMC-035 in Patients Undergoing Kidney Transplantation	23-03-16
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22
Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA	23-02-16
Guard Therapeutics International AB Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial	23-02-10
Guard Therapeutics International AB Announces Nomination Committee Appointments	22-12-20
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Other languages

Filters